| HOME >> BIOLOGY >> TECHNOLOGY |
-- a $20.2 million non-cash reduction in the carrying value of the
intangible asset related to Antizol(R) (fomepizole) as a result of the
approval and introduction of a generic competitor;
-- a $17.5 million charge related to a previously announced settlement
with the United States government, of which $1.0 million was paid in
2007;
-- $9.5 million of contract revenue resulting from milestone payments
under Jazz Pharmaceuticals' agreement with UCB; and
-- a $5.1 million gain on the divestiture of Cystadane(R) (betaine
anhydrous for oral solution).
Net loss for the year ended December 31, 2006 included a $31.6 million non-cash gain on extinguishment of a development financing obligation in connection with a terminated development program.
Research and development expenses for the quarter ended December 31, 2007 were $20.5 million, compared to $13.0 million for the quarter ended December 31, 2006. For the year ended December 31, 2007, research and development expenses were $69.8 million, compared to $55.0 million for the year ended December 31, 2006. The increase in research and development expenses in 2007 reflects expanded Phase III clinical trial activities for JZP-6, LUVOX CR scale-up and manufacturing costs and increased headcount.
Selling, general and administrative expenses for the quarter ended
December 31, 2007 were $28.0 million, compared to $12.5 million for the
quarter ended December 31, 2006. For the year ended December 31, 2007,
selling, general and administrative expenses were $78.5 million, compared
to $51.4 million for the year ended December 31, 2006. The increase in both
periods was primarily due to spending in preparation for the anticipated
launch of Once-A-Day LUVOX CR (fluvoxamine maleate) Extended-Release
Capsules, increased headcount and higher expenses to support the company's
sales force, offset
'/>"/>
| SOURCE Jazz Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |